FDA Clearance Tracker · P190033
AAV5 DetectCDx
Last checked: Nov 19, 2026Latest source record: Jun 29, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jun 29, 2023
Approval withdrawn
Time to decision
1,284 days
Received Dec 23, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P190033
- Device name
- AAV5 DetectCDx
- Applicant
- ARUP Laboratories
- Applicant location
- Salt Lake City, UT
- Received
- Dec 23, 2019
- Decided
- Jun 29, 2023
- Decision
- Approval withdrawn
- Supplements
- 1 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Assays to detect pre-existing antibodies to adeno-associated virus (AAV) viral vectors (QWQ)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of the AAV5 DetectCDx by ARUP Laboratories. This device is indicated for:The AAV5 Total Antibody Assay for ROCTAVIAN (valoctocogene roxaparvovec-rvox) Eligibility in Hemophilia A (AAV5 TAb Assay), or AAV5 DetectCDx, is a qualitative in vitro diagnostic test by electrochemiluminescence intended for detection of antibodies in human plasma collected in 3.2% sodium citrate that bind to the adeno-associated virus serotype 5 (AAV5). The AAV5 TAb Assay is indicated as an aid in the selection of adult hemophilia A patients for whom ROCTAVIAN treatment is being considered. Patients that are anti-AAV5 antibody positive (result of Detected) are not eligible for treatment with ROCTAVIAN; patients that are anti-AAV5 antibody negative (result of Not Detected) are eligible for treatment with ROCTAVIAN. This assay is for professional use and is a single-site assay performed at ARUP Laboratories.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QWQ (Assays to detect pre-existing antibodies to adeno-associated virus (AAV) viral vectors).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for ARUP Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.